The Use Of Antiplatelet Review And Post Percutaneous Coronary Intervention In Private Hospital Surabaya

Ike Dhiah Rochmawati

doi:10.32382/mf.v16i2.1761

The Use Of Antiplatelet Review And Post Percutaneous Coronary Intervention In Private Hospital Surabaya

Ike Dhiah Rochmawati

Abstract

Antiplatelets are medicines that stop cells in the blood (platelets) from sticking together and forming a clot, which may lead to a heart attack or stroke. Furthermore, the use of antiplatelet after percutaneous coronary intervention is one of the challenge encountered by the clinicians or hospital staff because it has to be calculated between the risk-benefit ratio. This study aims to evaluate the use of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. A retrospective study was used and data were obtained from patient records. The data obtained were analysed to know the relationship between age, gender, and type of drug combination associated with ischemic events. The patient demographics were analysed descriptively, and the comparison between age and sex group related to ischemic events was analysed using chi-square analysis. There was no statistical difference in ischemic events between age and sex group. The study reported that the most commonly used DAPT profile was the combination of Aspirin 100 mg - Clopidogrel 75 mg (38%) and Aspirin 100 mg - Ticagrelor 90 mg (28%). The profile of ischemic events in patients using the aspirin-clopidogrel combination was lower than that of the aspirin-ticagrelor combination.

Keywords: Antiplatelet, Percutaneous Coronary Intervention, Coronary Heart Disease

Full Text:

PDF

References

Becker et al., 2006, Sex Differences in Platelet Reactivity and Response to Low-Dose Aspirin Therapy , JAMA. 2006; 295(12):1420-1427

Borja I et al. , 2017, ESC guidlines for the management of acute myocardial infarction in patient presenting with persistent ST-segment elevation. European Heart Journal (2018) 39, 119-177

Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg G, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M. Derivation and validation of the predicting bleeding complications in patients undergoing stentimplantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025–1034.

D. Capodono, et al. , 2013, Antiplatelet therapy: new pharmacological agents and changing paradigms, J Thromb Haemost 2013 Jun:11 Suppl 1:316-29

Department of Health. 2006, Pharmaceutical Care for Coronary Heart Disease Patients: The Focus of Acute Coronary Syndrome , Jakarta: Directorate of Community Pharmacy Development and the DITJEN Clinic Pharmaceutical Development and Medical Devices

Dadjau, Yahya et al, 2016, Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting , Medicine (Baltimore). 2016 May;95 (22)

Eikelboom, W. John., 2012, Antithrombotic Therapy and Prevention of Thrombosis. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 9 th Edition, Volume 141, number 2

Han, Yaling, et al, 2005 , Cilostazol improves long-term outcomes after coronary stent implantation, American Heart J. 2005 Sep;150(3):568

Hannan, et al, 2016, Patient With Chronic Total Occlusions Undergoing Percutaneous Coronary Interventions: Characteristics, Success, and Outcomes. Circ Cardiovasc Interv 2016 May;9(5)

Harter et al, 2015, Anticoagulant Drug Therapy: A Review, West J Emerg Med 2015 Jan:16(1):11-7

John F. Beltrame, Rachel Dreyer and Rosanna Tavella (March 16th 2012). Epidemiology of Coronary Artery Disease, Coronary Artery Disease - Current Concepts in Epidemiology, Pathophysiology, Diagnostics and Treatment, David Gaze, IntechOpen, DOI: 10.5772/29030. Available from: https://www.intechopen.com/books/coronary-artery-disease-current-concepts-in-epidemiology-pathophysiology-diagnostics-and-treatment/epidemiology-of-coronary-artery-disease

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal (2019)00, 1-71

Maas, Appelman, 2010, Gender Differences in Coronary Heart Disease. Neth Heart J 2010;18:598-603

Ministry of Health Republic of Indonesia., 2014, Infodatin: Heart Health Situation, Data and Information Center Ministry of Health Republic of Indonesia, 2, (online)

Ministry of Health, 2016, Standard Rates of Health Services in the administration of the Health Insurance Program, Health Minister Regulation No. 52

Miyazaki, Yosuke et al, 2017, Single or dual Antiplatelet therapy after PCI, Nat Rev Cardiol 207 May;14(5):294-303

Montalescot G, Drobinski G, Maclouf J, Maillet F, Salloum J, Ankri A, Kazatchkine M, Eugene L, Thomas D, Grosgogeat Y. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 1991;84:2054–2062.

Nusca, Annunziata, et al, 2013, Influence of Platelet Reactivity on Clinical Outcome of Patients with Stable Coronary Artery Disease. J Cardiovasc Transl Res.213 Jun;6(3):346-54

Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177–1184.

Piccolo and Windecker, 2016, Dual Antiplatelet Therapy in Percutaneous Coronary Intervention , AHA journal

Potter, P., & Perry, A, 2005, Textbook of Fundamentals of Nursing: Concepts, Process and Practice , 4 th ed., Vol 1, Jakarta: EGC

Richard A. Lange., And L. David Hillis, 2013, Coronary Revascularization in Context , N Engl J Med 2009;360:1024-1026

Scott, et al., 2015, Antiplatelet Drug Interaction with Proton Pump Inhibitors, NIH Public Access Author Manuscript, Volume 10, number 2.

Titin Andri Wihastuti., Sri Andarini., And Teuku Heriansyah., 2016, Basic Pathophysiology of Nursing in Coronary Heart Disease: Vascular Inflammation , Malang: UB Press

Tsang, Teresa S. M., et al, 2003, Prediction of Risk for First Age-Related Cardiovascular Events in an Elderly Population: The Incremental Value of Echocardiography. J Am Coll Cardiol. 2003 Oct 1 ;42(7): 1199-205

Valgimigli M et al. , 2017, ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal (2018) 39, 213-254

Verdoia M., et al, 2016, Advanced Age and High-Residual Platelet Reactivity in Patients Receiving Dual Antipletelet Therapy with Clopidogrel or Ticagrelor. J Thromb Haemost. 2016 Jan;14(1): 57-64

Wiviott, D. Stephen et al , 2007, Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes, N Engl J Med 2007; 357: 2001-2015

WHO, 2011, Global Atlas of cardiovascular disease prevention and control.

Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA 2016;315:1735–1749.

DOI: https://doi.org/10.32382/mf.v16i2.1761